Author Archives: Julian Upton
By Julian Upton | Published: April 22, 2014
What’s the opposite of Black Tuesday? White Tuesday? Bright Tuesday? Because Tuesday the stock market was buzzing following the news that Novartis is to acquire GSK’s cancer drugs business, while selling its vaccines division to GSK. With the speculation of a $100bn Pfizer bid for AstraZeneca and Valeant Pharmaceuticals added in, prices went soaring. As of […]
By Julian Upton | Published: April 4, 2014
A report published yesterday provides recommendations for combating the “significant inequalities” affecting access to quality cancer care in Europe.
By Julian Upton | Published: March 19, 2014
Innovation as a consideration of value-based pricing decisions will be conspicuous by its absence in future NICE decisions. Omar Ali, a UK formulary development pharmacist and consultant to NICE, speaking at eyeforpharma’s Barcelona 2014 conference on Wednesday, explained that the UK price watchdog will prioritize considerations of wider societal benefit and unmet need as it […]
By Julian Upton | Published: February 26, 2014
Bioscience research in China is set to overtake the United States within the next five to ten years, according to data from search engine CiteAb.
By Julian Upton | Published: February 11, 2014
Approximately $12.7 billion has been invested in Latin America’s (LATAM’s) pharmaceutical market through mergers and acquisitions (M&As) in recent years. And with untapped potential identified in countries across the region, companies are expected to seize upon further opportunities to drive future growth, says a new report from GlobalData.